Firms

SYNthesis BioVentures

SYNthesis BioVentures

Parkville, Melbourne, Victoria, Australia

synthesisbioventures.com

SYNthesis BioVentures invests in Australian early-stage therapeutics, supporting projects from discovery and preclinical proof of concept through IND-enabling studies, early clinical development and pre-IPO financing. Its strategy covers small-molecule drugs, biologics, and cell and gene therapies across diseases with substantial unmet need. It uses the SYNthesis Group’s research, drug-development and commercialisation resources to help portfolio companies develop assets and reach financing or partnering milestones. Published investments include neuron-replacement cell therapy developer Skin2Neuron and federated AI and quantum-chemistry drug-design company Qubigen. The legal investment manager is SYNthesis BioVentures Pty Ltd, based at Melbourne’s Bio21 Institute; it manages SYNthesis BioVentures Fund I, a stapled early-stage venture-capital partnership and unit trust.

Founded
2022
Type
Venture capital

Funds1

  • SYNthesis BioVentures Fund I—

    A stapled therapeutics venture-capital fund comprising SYNthesis BioVentures I, LP (L0000591U) and SYNthesis BioVentures Trust I. The manager’s September2025 legal disclosure confirms the structure and unconditional ESVCLP registration. Recent actual investment activity is documented, but a completed recent fundraising close, final corpus and public closing-announcement date are unverified. Partnership and trust are components of this single published fund, not two inferred capital raises.

Team

Operations and support

Amir ZalcensteinManaging Director
Andrew F. WilksManaging Director
Fabio TurattiManaging Director
Martine KeenanFund Chief Scientific Officer (published May2023; current tenure unverified)
Simon PrestonFund Investment Analyst (published May2023; current tenure unverified)

Co-investing

Artesian

Investments